Tonghua Dongbao Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Tonghua Dongbao Pharmaceutical's earnings have been declining at an average annual rate of -0.09%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 1.3% per year. Tonghua Dongbao Pharmaceutical's return on equity is 5.3%, and it has net margins of 14%.
Key information
-0.09%
Earnings growth rate
0.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -1.3% |
| Return on equity | 5.3% |
| Net Margin | 14.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Tonghua Dongbao Pharmaceutical (SHSE:600867) Has A Pretty Healthy Balance Sheet
Oct 22
Tonghua Dongbao Pharmaceutical Co., Ltd.'s (SHSE:600867) Earnings Haven't Escaped The Attention Of Investors
Sep 30Some May Be Optimistic About Tonghua Dongbao Pharmaceutical's (SHSE:600867) Earnings
Sep 06Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) Analysts Just Slashed This Year's Estimates
Sep 05Calculating The Intrinsic Value Of Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867)
Aug 22Tonghua Dongbao Pharmaceutical (SHSE:600867) Has A Rock Solid Balance Sheet
Jun 19Improved Earnings Required Before Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) Shares Find Their Feet
May 23Revenue & Expenses Breakdown
How Tonghua Dongbao Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,432 | 341 | 1,203 | 114 |
| 30 Jun 24 | 2,449 | 453 | 1,100 | 107 |
| 31 Mar 24 | 3,001 | 1,132 | 1,074 | 104 |
| 31 Dec 23 | 3,075 | 1,168 | 1,067 | 105 |
| 30 Sep 23 | 2,771 | 939 | 1,063 | 100 |
| 30 Jun 23 | 2,757 | 884 | 1,055 | 132 |
| 31 Mar 23 | 2,556 | 1,001 | 1,063 | 145 |
| 31 Dec 22 | 2,778 | 1,582 | 1,107 | 147 |
| 30 Sep 22 | 2,912 | 1,643 | 1,189 | 161 |
| 30 Jun 22 | 2,993 | 1,820 | 1,258 | 152 |
| 31 Mar 22 | 3,332 | 1,803 | 1,266 | 158 |
| 31 Dec 21 | 3,268 | 1,308 | 1,257 | 167 |
| 30 Sep 21 | 3,162 | 1,242 | 1,202 | 143 |
| 30 Jun 21 | 3,079 | 1,060 | 1,149 | 130 |
| 31 Mar 21 | 2,996 | 989 | 1,119 | 123 |
| 31 Dec 20 | 2,892 | 930 | 1,092 | 107 |
| 30 Sep 20 | 2,906 | 879 | 1,103 | 104 |
| 30 Jun 20 | 2,817 | 820 | 1,074 | 94 |
| 31 Mar 20 | 2,781 | 815 | 1,039 | 81 |
| 31 Dec 19 | 2,777 | 811 | 1,011 | 78 |
| 30 Sep 19 | 2,741 | 839 | 962 | 81 |
| 30 Jun 19 | 2,664 | 834 | 871 | 87 |
| 31 Mar 19 | 2,688 | 838 | 871 | 96 |
| 31 Dec 18 | 2,693 | 839 | 866 | 98 |
| 30 Sep 18 | 2,701 | 876 | 848 | 104 |
| 30 Jun 18 | 2,827 | 963 | 819 | 143 |
| 31 Mar 18 | 2,699 | 900 | 812 | 118 |
| 31 Dec 17 | 2,545 | 837 | 798 | 97 |
| 30 Sep 17 | 2,414 | 789 | 775 | 65 |
| 30 Jun 17 | 2,332 | 736 | 822 | 0 |
| 31 Mar 17 | 2,154 | 690 | 744 | 0 |
| 31 Dec 16 | 2,040 | 641 | 720 | 0 |
| 30 Sep 16 | 1,909 | 604 | 671 | 0 |
| 30 Jun 16 | 1,779 | 546 | 676 | 0 |
| 31 Mar 16 | 1,722 | 533 | 684 | 0 |
| 31 Dec 15 | 1,669 | 493 | 673 | 0 |
| 30 Sep 15 | 1,661 | 450 | 667 | 0 |
| 30 Jun 15 | 1,576 | 393 | 648 | 0 |
| 31 Mar 15 | 1,521 | 321 | 649 | 0 |
| 31 Dec 14 | 1,451 | 280 | 633 | 0 |
| 30 Sep 14 | 1,369 | 215 | 681 | 0 |
| 30 Jun 14 | 1,308 | 216 | 630 | 0 |
| 31 Mar 14 | 1,265 | 198 | 604 | 0 |
| 31 Dec 13 | 1,204 | 184 | 586 | 0 |
Quality Earnings: 600867 has a large one-off loss of CN¥300.8M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 600867's current net profit margins (14%) are lower than last year (33.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600867's earnings have declined by 0.09% per year over the past 5 years.
Accelerating Growth: 600867's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 600867 had negative earnings growth (-63.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).
Return on Equity
High ROE: 600867's Return on Equity (5.3%) is considered low.